期刊
BIOMARKER RESEARCH
卷 9, 期 1, 页码 -出版社
BMC
DOI: 10.1186/s40364-021-00315-7
关键词
Neoantigen vaccine; Cancer immunotherapy; Precision medicine
资金
- National Natural Science Foundation of China [81802857]
- National Key Research and Development Program of China [2018YFC1313400]
- National Science and Technology Major Project of China [2020ZX09201-009]
Neoantigens, derived from non-synonymous mutations, have emerged as attractive targets for cancer immunotherapy. Computational prediction and clinical trials have shown promising efficacy and safety, leading to a new era in cancer immunotherapy.
Neoantigens, a type of tumor-specific antigens derived from non-synonymous mutations, have recently been characterized as attractive targets for cancer immunotherapy. Owing to the development of next-generation sequencing and utilization of machine-learning algorithms, it has become feasible to computationally predict neoantigens by depicting genetic alterations, aberrant post-transcriptional mRNA processing and abnormal mRNA translation events within tumor tissues. Consequently, neoantigen-based therapies such as cancer vaccines have been widely tested in clinical trials and have demonstrated promising safety and efficacy, opening a new era for cancer immunotherapy. We systematically summarize recent advances in the identification of both personalized and public neoantigens, neoantigen formulations and neoantigen-based clinical trials in this review. Moreover, we discuss future techniques and strategies for neoantigen-based cancer treatment either as a monotherapy or as a combination therapy with radiotherapy, chemotherapy or immune checkpoint inhibitors.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据